| 08:00 |
Registration |
| |
Opening |
| 09:00 |
Opening and welcome |
Frank de Wolf
(Stichting HIV Monitoring, Amsterdam; Imperial College, London, UK) |
Session 1: Epidemiology |
| Chairs: Marianne van der Sande (Centre for Infectious Disease Control, RIVM, Bilthoven) / Ton Coenen (Aids Fonds, Amsterdam) |
| |
| 09:10 |
Developments in the HIV epidemic in the Netherlands |
Frank de Wolf
(Stichting HIV Monitoring, Amsterdam; Imperial College, London, UK) |
| 09:30 |
Transmission of HIV resistant to non-nucleoside RT inhibitors is rising in MSM in Europe |
Dineke Frentz
(Erasmus MC, Rotterdam)
|
| 09:45 |
Outbreaks and increasing trends of HIV and STI among MSM in Europe |
Eline Op de Coul
(Centre for Infectious Disease Control, RIVM, Bilthoven)
|
| 10:00 |
Comorbidity and Ageing in HIV-1-infection |
Judith Schouten
(Amsterdam Institute for Global Health and Development (AIGHD), AMC, UvA, Amsterdam)
|
| |
| 10:15 |
Coffee break |
| |
Session 2: Treatment |
| Chairs: Suzanne Geerlings (AMC, UvA, Amsterdam) / Ineke van der Ende (Erasmus MC, Rotterdam) |
| |
| 10:45 |
Prospects for HIV eradication |
Steven Deeks
(AIDS Research Institute at UCSF, San Francisco, CA, USA) |
| 11:15 |
Anal intraepithelial neoplasia (AIN): precursor lesions for anal cancer in HIV positive patients |
Henry de Vries
(AMC, UvA, Amsterdam) |
| 11:35 |
Modest Deviations from Optimal Adherence to Antiretroviral Therapy Promote Residual HIV-1 Replication in the Absence of Virological Rebound in Plasma |
Alexander Pasternak
(AMC, UvA, Amsterdam)
|
| 11:50 |
Sustained efficacy with low and similar rates of virologic failures in second year observed with rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment naive, HIV-1 infected adults - pooled 96-week ECHO and THRIVE analysis |
Bart Rijnders
(Erasmus MC, Rotterdam)
|
| |
| 12:05 |
Lunch and Poster Presentations |
| |
Session 3: Pathogenesis |
| Chairs: Joep Lange (AIGHD, AMC, UvA, Amsterdam) / Frank Miedema (UMC, Utrecht) |
| |
| 13:30 |
SIVs, factors related to transmission and emergence in humans |
Martine Peeters
(Institute of Research and Development (IRD), Montpellier, France) |
| 14:00 |
Long-term disturbances of the CD8 T-cell compartment after 5 years of successful HAART |
Ellen Veel
(UMC, Utrecht)
|
| 14:15 |
Predicted compensatory mutations increase the replicative capacity of the HIV 1 HLA-B57 T242N escape mutant in vitro. |
Esther Gijsbers
(AMC, UvA, Amsterdam)
|
| 14:30 |
HLA-related protection against progression to AIDS: a different mechanism for HLA-B27 and HLA-B57 |
Hilde Spits
(UMC, Utrecht)
|
| |
| 14:45 |
Tea break |
| |
Session 4: Prevention |
| Chairs: Frank de Wolf (Stichting HIV Monitoring, Amsterdam; Imperial College, London, UK) |
| |
| 15:15 |
HIV and TB : The Prevention Revolution |
Linda-Gail Bekker
(Desmond Tutu HIV Centre, Cape Town, South Africa) |
| 15:45 |
HIV vaccine elicited immunity: T or B? That's the question. |
Hanneke Schuitemaker
(Crucell, Leiden; AMC, UvA, Amsterdam) |
| 16:05 |
Delay of entry into care in HIV positive individuals |
Maaike van Veen
(Centre for Infectious Disease Control, RIVM, Bilthoven) |
| 16:20 |
High HIV incidence among MSM prescribed post exposure prophylaxis in Amsterdam, 2000-2009: indications for ongoing sexual risk behaviour |
Ineke Stolte
(Department of Infectious Diseases, Public Health Service, Amsterdam) |
| |
Closing Keynote |
| Chair: Joep Lange (AIGHD, AMC, UvA, Amsterdam) |
| |
| 16:35 |
HIV vaccines: current status and future prospects |
Richard Koup
(NIH/Vaccine Research Centre, Bethesda, MD, USA) |
| |
| 17:20 |
Drinks |
